SEC Comment Letter for Iterum Therapeutics plc (ITRM) (CIK 0001659323) (ITRM) — Feb 12, 2025
Iterum Therapeutics plc (ITRM) (CIK 0001659323)
Date: Feb. 12, 2025 · CIK: 0001659323 · Accession: 0000000000-25-001526
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284774
Letter
February 11, 2025 Corey Fishman President and Chief Executive Officer Iterum Therapeutics plc 200 South Wacker Dr., 31st Floor Chicago, IL 60606 Re:Iterum Therapeutics plc Registration Statement on Form S-3 Filed February 7, 2025 File No. 333-284774 Dear Corey Fishman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Brian A. Johnson
Show Raw Text
February 11, 2025
Corey Fishman
President and Chief Executive Officer
Iterum Therapeutics plc
200 South Wacker Dr., 31st Floor
Chicago, IL 60606
Re:Iterum Therapeutics plc
Registration Statement on Form S-3
Filed February 7, 2025
File No. 333-284774
Dear Corey Fishman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Brian A. Johnson